| Not Yet Recruiting | Remapping Text in Sentence and Word Tasks to Aid Reading With Central Vision Loss NCT07216924 | University of Minnesota | N/A |
| Not Yet Recruiting | Artificial Intelligence-assisted Diagnosis in Ophthalmology NCT07497815 | Marisse Masis-Solano | — |
| Not Yet Recruiting | A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003) NCT07496567 | EyeBiotech Ltd. | Phase 2 / Phase 3 |
| Not Yet Recruiting | Evaluate the Efficacy of Faricimab in Patients With Neovascular Age-related Macular Degeneration NCT07367282 | Junyeop Lee | Phase 4 |
| Recruiting | A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002) NCT07440225 | EyeBiotech Ltd. | Phase 2 / Phase 3 |
| Recruiting | Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium NCT04008121 | MediBeacon | EARLY_Phase 1 |
| Recruiting | Natural History Study of Inherited Retinal Diseases NCT07085533 | Zhongmou Therapeutics | — |
| Recruiting | A Prospective Observational Study to Assess the Reliability and Validity of the MLSDT NCT06805474 | Nanoscope Therapeutics Inc. | — |
| Recruiting | A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic NCT06779773 | Astellas Pharma Global Development, Inc. | — |
| Enrolling By Invitation | Implementation of the Intravitreal Injection Administered by Nurses NCT06511700 | Corporacion Parc Tauli | — |
| Not Yet Recruiting | Vision Improvement for Patients With Age-Related Macular Degeneration NCT06198452 | VIS, Inc. | N/A |
| Recruiting | A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrop NCT06635148 | Janssen Research & Development, LLC | Phase 2 |
| Recruiting | Safety & Efficacy of Eyecyte-RPE™ in Patients With Geographic Atrophy Secondary to Dry Age-related Macular Deg NCT06394232 | Eyestem Research Pvt. Ltd. | Phase 1 / Phase 2 |
| Unknown | Developing Better Computerised Vision Tests (CVTV) NCT06224751 | Guy's and St Thomas' NHS Foundation Trust | — |
| Recruiting | A Efficacy and Safety Study of Ranibizumab 10mg/ml Injection (Incepta) in Patients With Diabetic Macular Edema NCT06305416 | Incepta Pharmaceuticals Ltd | Phase 3 |
| Withdrawn | MacuTest Website for Personalized AMD Risk Prediction and Prevention NCT05675917 | University Hospital, Bordeaux | N/A |
| Unknown | Single-center Study Measuring OSDI Dry Eye Score in Patients Undergoing an Anti-VEGF Induction Protocol NCT06262737 | University Hospital, Clermont-Ferrand | — |
| Completed | Evaluation of The Performance of Retinow AI Software NCT06645964 | Retinow Health Technologies and R&D Industry Joint Stock Company | — |
| Active Not Recruiting | A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AM NCT05839041 | Aviceda Therapeutics, Inc. | Phase 2 |
| Active Not Recruiting | Recurrence and Predictive OCT Biomarkers in Quiescent Neovascular AMD NCT06717139 | St. Erik Eye Hospital | — |
| Active Not Recruiting | Investigating Geographic Atrophy Insights (i-GAIN) Natural History Study NCT05797896 | Complement Therapeutics | — |
| Completed | A Randomized, Double Masked, Parallel Group, Dose-finding Study to Evaluate SYL1801 in Patients With Neovascul NCT05637255 | Sylentis, S.A. | Phase 2 |
| Recruiting | NYSCF Scientific Discovery Biobank NCT06203106 | New York Stem Cell Foundation Research Institute | — |
| Completed | Scotoma Perimetry Oculomotor Training NCT05456581 | University of Alabama at Birmingham | N/A |
| Recruiting | Factors in Learning And Plasticity: Macular Degeneration NCT05454124 | University of Alabama at Birmingham | N/A |
| Active Not Recruiting | Factors in Learning And Plasticity: Healthy Vision NCT05439759 | University of Alabama at Birmingham | N/A |
| Unknown | Retinal Oxygenation Estimation Trial With Mantis Photonics Hyperspectral Camera NCT05566626 | Mantis Photonics AB | N/A |
| Recruiting | Safety and Efficacy of Autologous Transplantation of iPSC-RPE in the Treatment of Macular Degeneration NCT05445063 | Beijing Tongren Hospital | Phase 1 |
| Unknown | Pistachios and Neural Macular Pigment NCT05283941 | Tufts University | N/A |
| Recruiting | Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for NAION NCT05147701 | The Foundation for Orthopaedics and Regenerative Medicine | Phase 1 |
| Enrolling By Invitation | Quest to Analyze One Thousand Humans Meditating NCT06583395 | Tobias Moeller-Bertram | — |
| Unknown | High Resolution Optical Coherence Tomography NCT05130385 | Insel Gruppe AG, University Hospital Bern | — |
| Completed | Fundus Image-guided Focal Electroretinography, Usability Study NCT05100511 | Maculaser Oy | N/A |
| Terminated | Visual Telerehabilitation in AMD Patients NCT04685824 | Michael Reber | N/A |
| Completed | Analysis of naïve Patients With Age-related Macular Degeneration Neovascular Type and Treated With Ranibizumab NCT04988178 | Brugmann University Hospital | — |
| Unknown | Study of New Mutations in Cone Disorders NCT04658251 | University Hospital, Lille | — |
| Recruiting | Learning Study: Improving Vision in Adults With Macular Degeneration NCT04762368 | University of Waterloo | N/A |
| Terminated | A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Neovascular Age-related Macular Degenerat NCT04684394 | Gemini Therapeutics, Inc. | Phase 2 |
| Completed | Evaluation of the Retinal Health Monitoring System Thickness Module NCT04499703 | Kubota Vision Inc. | — |
| Unknown | Prediction of Progression of Age-Related Macular Degeneration NCT04640649 | University of Illinois at Chicago | N/A |
| Active Not Recruiting | Study of Zifibancimig in Participants With Neovascular Age-related Macular Degeneration NCT04567303 | Hoffmann-La Roche | Phase 1 / Phase 2 |
| Terminated | A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Dry Age-related Macular Degeneration NCT04643886 | Gemini Therapeutics, Inc. | Phase 2 |
| Completed | A Phase 3 Safety and Efficacy Study of Intravitreal Administration of Zimura (Complement C5 Inhibitor) NCT04435366 | IVERIC bio, Inc. | Phase 3 |
| Withdrawn | Study Evaluating Retinal Health Monitoring System Thickness Module NCT04428242 | Kubota Vision Inc. | — |
| Completed | Comparing Vision Tests in a Virtual Reality Headset to Existing Analogues NCT04714424 | Icahn School of Medicine at Mount Sinai | — |
| Completed | First in Human Study to Evaluate the Safety and Tolerability of GEM103 in Geographic Atrophy Secondary to Dry NCT04246866 | Gemini Therapeutics, Inc. | Phase 1 |
| Completed | Advancing Understanding of Transportation Options NCT04141891 | University of Colorado, Denver | N/A |
| Completed | Improving Vision in Adults With Macular Degeneration NCT04111068 | University of Waterloo | N/A |
| Terminated | A Study to Test How Well Different Doses of BI 754132 Are Tolerated in Patients With an Advanced Form of Age-r NCT04002310 | Boehringer Ingelheim | Phase 1 |
| Completed | Study to Collect Safety and ECG Data on Brolucizumab 6 mg Intravitreal Treatment in Patients With Wet AMD NCT03954626 | Novartis Pharmaceuticals | Phase 3 |
| Completed | Comparing the Efficacy and Safety of Biosimilar Candidate Xlucane Versus Lucentis® in Patients With nAMD NCT03805100 | Xbrane Biopharma AB | Phase 3 |
| Completed | Long Term Safety of Cooling Anesthesia for Intravitreal Injection NCT03956797 | Recens Medical, Inc. | N/A |
| Completed | GOLDEN STUDY: A Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRx in Participants With Geo NCT03815825 | Ionis Pharmaceuticals, Inc. | Phase 2 |
| Completed | Aflibercept Injection Into the Vitreous Body of the Eye: Study to Learn More About Patient Relevant Outcomes, NCT03714308 | Bayer | — |
| Terminated | GTSCOPE - To Evaluate the Natural Progression of Dry Age-related Macular Degeneration (AMD) NCT03894020 | Gyroscope Therapeutics Limited | — |
| Terminated | FOCUS: A Phase I/II First in Human Study to Evaluate the Safety and Efficacy of GT005 Administered in Subjects NCT03846193 | Gyroscope Therapeutics Limited | Phase 1 / Phase 2 |
| Completed | Cooling Anesthesia for Intravitreal Injection NCT03732287 | Recens Medical, Inc. | Phase 1 / Phase 2 |
| Completed | BCI and Evaluation of Visual and Task Performance in Subjects With Eye Diseases NCT03318549 | University of Miami | N/A |
| Withdrawn | Effect of Vitrectomy on the Evolution of Refractory Diabetic Macular Edema NCT03603990 | Fondation Ophtalmologique Adolphe de Rothschild | N/A |
| Completed | The Effect of Duration Between Sessions on Microperimetric Biofeedback Training in Patients With Maculopathies NCT05904444 | Aier Eye Hospital, Guangzhou | N/A |
| Completed | A Study to Evaluate Abicipar Pegol for Safety and Treatment Effect in Participants With Neovascular Age-relate NCT03539549 | Allergan | Phase 2 |
| Unknown | JY028 Single Vitreous Injection in a Phase 1 Clinical Trial in nAMD Patients NCT03725566 | Beijing Tongren Hospital | N/A |
| Completed | An Integrated Analysis of the Effectiveness of Intravitreal (IVT) Aflibercept (Eylea) in Routine Clinical Prac NCT03521895 | Bayer | — |
| Withdrawn | Efficacy and Safety Study of CNTO 2476 in Participants With Visual Acuity Impairment Associated With Geographi NCT02895815 | Janssen Pharmaceutical K.K. | Phase 2 |
| Completed | A Study in Patients With Wet Age-related Macular Degeneration or Diabetic Macular Edema to Assess the freQuenc NCT03470103 | Bayer | — |
| Completed | Evaluate the Effectiveness of Intravitreal (IVT) Aflibercept Injection in Clinical Practice in naïve Patients NCT03411941 | Bayer | — |
| Completed | "Night Vision and Carotenoids" NCT04741763 | Robert Davis | N/A |
| Completed | Evaluation of a New Eye-specific Multivitamin Formula in Participants at Risk of Age-related Macular Degenerat NCT03946085 | Guardion Health Sciences, Inc. | N/A |
| Completed | Safety and Pharmacokinetics of Abicipar Pegol Intravitreal Injections in Japanese Patients With Neovascular AM NCT03335852 | Allergan | Phase 1 |
| Terminated | Enhancing the Lucentis (Ranibizumab) Management of Choroidal Neovascular Membranes With Hyperspectral Imaging NCT03105609 | Center for Eye Research Australia | — |
| Recruiting | Diagnostic Possibilities in Ophthalmological Diseases Using Swept Source Optical Coherence Tomography NCT06074731 | Johannes Kepler University of Linz | — |
| Completed | Effect Aflibercept on Ocular Perfusion NCT03804099 | Augenabteilung Allgemeines Krankenhaus Linz | Phase 4 |
| Completed | Correlation Between Visual Acuity Measurements, Quality of Life and Morphological Parameters in Wet AMD Patien NCT03438669 | Dr. med. Katja Hatz | — |
| Terminated | Deficits, Adaptation and Cerebral Functional Reorganization of Visual Retinotopic Treatments During Normal and NCT03133117 | University Hospital, Grenoble | N/A |
| Completed | Safety and Pharmacokinetics of Abicipar Pegol Intravitreal Injections in Patients With Neovascular AMD NCT02859766 | Allergan | Phase 1 |
| Completed | Non-Damaging Photothermal Therapy of Non-exudative Age Related Macular Degeneration NCT02569892 | Stanford University | N/A |
| Completed | Prospective Observational Study to Assess Effectiveness of Intravitreal Aflibercept in Patients With Wet Macul NCT02821247 | Bayer | — |
| Unknown | Ocular Imaging Study Using Advanced OCT NCT02827071 | University of California, Los Angeles | — |
| Completed | Ocular Discomfort Assessment After Intravitreal Injections NCT02806830 | Centre Hospitalier Intercommunal Creteil | N/A |
| Unknown | Evaluation of Visual Function and Driving Health Using Ocusweep in Patients Suffering From Wet Age-related Mac NCT02747368 | Turku University Hospital | N/A |
| Completed | Technology-based Eye Care Services (TECS) Compare NCT02558712 | Emory University | N/A |
| Unknown | Treatment of Age-related Macular Degeneration by Fetal Retinal Pigment Epithelial Cells Transplantation NCT02868424 | The First Affiliated Hospital with Nanjing Medical University | EARLY_Phase 1 |
| Recruiting | Stem Cell Ophthalmology Treatment Study II NCT03011541 | MD Stem Cells | N/A |
| Completed | Evaluation of Physician and Patient Knowledge of Safety and Safe Use Information for Aflibercept NCT02615496 | Bayer | — |
| Completed | A Study to Evaluate the Safety and Clinical Response of Subretinal Administration of CNTO 2476 in Participants NCT02659098 | Janssen Research & Development, LLC | Phase 2 |
| Completed | Managing Neovascular (Known as "Wet") Age-related Macular Degeneration Over 2 Years Using Different Treatment NCT02581891 | Bayer | Phase 4 |
| Completed | Assessment of Scan Quality of Sparse OCT Retina Scanner (MimoStudy01) NCT02555995 | University of Bern | N/A |
| Completed | Efficacy and Safety of Two Different Aflibercept Regimens in Subjects With Neovascular Age-related Macular Deg NCT02540954 | Bayer | Phase 3 |
| Completed | Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab NCT02510794 | Genentech, Inc. | Phase 2 |
| Completed | Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of OPT-302 With or Without Lucentis™ in Pat NCT02543229 | Opthea Limited | Phase 1 |
| Unknown | Analysis of Aqueous and Vitreous Humor NCT02067013 | California Retina Consultants | Phase 2 |
| Unknown | MP3 (Microperimeter 3) Reproducibility in Healthy Subjects and Macular Patients NCT02941406 | Vienna Institute for Research in Ocular Surgery | — |
| Completed | A Safety and Efficacy Study of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneratio NCT02462928 | Allergan | Phase 3 |
| Completed | Safety and Efficacy of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration NCT02462486 | Allergan | Phase 3 |
| Completed | Photodynamic Therapy for PDA in NV AMD NCT02452840 | Duke University | — |
| Unknown | Clinical Study of Subretinal Transplantation of Human Embryo Stem Cell Derived Retinal Pigment Epitheliums in NCT02749734 | Southwest Hospital, China | Phase 1 / Phase 2 |
| Completed | Study to Evaluate Home Vision Testing in Participants Who Receive Ranibizumab (Lucentis®) NCT02420132 | Hoffmann-La Roche | — |
| Terminated | X-82 to Treat Age-related Macular Degeneration NCT02348359 | Tyrogenex | Phase 2 |
| Unknown | Ziv-aflibercept in Ocular Disease Requiring Anti-VEGF Injection NCT02486484 | Rafic Hariri University Hospital | Phase 2 |
| Completed | The Focal Electro-Oculogram in Macular Disease NCT02225119 | National Eye Institute (NEI) | — |
| Withdrawn | Investigating Optical and Neural Causes of Vision Loss NCT00926913 | US Department of Veterans Affairs | — |
| Terminated | Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration NCT02222207 | Bayer | Phase 2 |
| Terminated | Study of the Intravitreal Implantation of NT-503-3 Encapsulated Cell Technology (ECT) for the Treatment of Rec NCT02228304 | Neurotech Pharmaceuticals | Phase 1 / Phase 2 |
| Completed | Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study NCT02390245 | Wills Eye | N/A |
| Completed | A Study of Abicipar Pegol in Japanese Patients With Neovascular Age-related Macular Degeneration NCT02181504 | Allergan | Phase 2 |
| Completed | Treatment -Resistant Neovascular Age-Related Macular Degeneration NCT02332941 | Washington University School of Medicine | Phase 1 |
| Completed | Development of a Device to Measure Dark Adaptation NCT02090751 | University of Manchester | — |
| Completed | A Study of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration NCT02181517 | Allergan | Phase 2 |
| Terminated | Efficacy and Safety of Lucentis® Use in Patients With Diabetic Macular Edema Evaluating a Spaced Out Follow-up NCT02032173 | Novartis Pharmaceuticals | Phase 3 |
| Terminated | A Safety and Efficacy Study of Brimonidine Intravitreal Implant in Geographic Atrophy Secondary to Age-related NCT02087085 | Allergan | Phase 2 |
| Completed | Eylea Post Marketing Surveillance(PMS) NCT01783925 | Bayer | — |
| Completed | EAGLE: Evaluating Genotypes Using Intravitreal Aflibercept Injection NCT02689518 | University of California, San Diego | Phase 4 |
| Terminated | A Study Testing if Medicine Can Make Pigment Epithelium Detachments Regress and Stabilize the Vision in Eyes NCT01746875 | Norwegian University of Science and Technology | N/A |
| Completed | A Study of RO6867461 Administered in Single- and Multiple-Ascending Doses in Patients With Wet Age-Related Mac NCT01941082 | Hoffmann-La Roche | Phase 1 |
| Completed | Aflibercept After Ranibizumab in Exudative Age-related Macular Degeneration NCT02157077 | Centre Hospitalier Intercommunal Creteil | Phase 3 |
| Completed | Evaluation of Changes in Visual Acuity in Patients With Diabetic Macular Edema (DME) Starting Treatment With a NCT01771081 | Bayer | — |
| Completed | Repeated Eye Injections of Aflibercept for Treatment of Wet Age Related Macular Degeneration NCT01773954 | MidAtlantic Retina | N/A |
| Completed | Drusen Morphology Changes in Nonexudative Age-related Degeneration After Oral Antioxidants Supplementation NCT02264938 | Germans Trias i Pujol Hospital | N/A |
| Completed | EYLEA Age-Related Macular Degeneration (AMD) Post-marketing Surveillance in Japan NCT01756248 | Bayer | — |
| Completed | EYLEA [AMD-QOL(Age-Related Macular Degeneration-Quality of Life)] Post-marketing Surveillance in Japan NCT01756261 | Bayer | — |
| Completed | Treat & Extend Treatment With 0.5mg Ranibizumab vs Monthly Treatment With 0.5mg Ranibizumab NCT01748292 | Charles C Wykoff, PhD, MD | Phase 3 |
| Unknown | An Open-label Study to Evaluate the Clinical and Economic Benefits of I-Ray in Patients With Choroidal Neovasc NCT01521065 | Oraya Therapeutics, Inc. | Phase 2 |
| Unknown | Stem Cell Ophthalmology Treatment Study NCT01920867 | MD Stem Cells | N/A |
| Completed | Study to Assess the EffectiVeness of exIsting Anti-vascular Endothelial groWth Factor (Anti-VEGF) Treatment Re NCT01933152 | Bayer | — |
| Completed | Effect of Omega-3-fatty Acids on Blood Levels Omega-3 Fatty Acids in Patients With Age-related Macular Degener NCT01653184 | Wills Eye | N/A |
| Completed | Study of Human Central Nervous System Stem Cells (HuCNS-SC) in Age-Related Macular Degeneration (AMD) NCT01632527 | StemCells, Inc. | Phase 1 / Phase 2 |
| Recruiting | Analysis of Biomarkers From Patients With Chorioretinal Diseases NCT02026843 | Kyungpook National University Hospital | — |
| Completed | A Safety And Efficacy Study Of ALG-1001 In Human Subjects With Wet Age-Related Macular Degeneration NCT01749891 | Allegro Ophthalmics, LLC | Phase 1 / Phase 2 |
| Terminated | Biological Sample Collection for Research and Biobanking NCT04270604 | New York Stem Cell Foundation Research Institute | — |
| Completed | The Impact of Ocular Diseases on Driving: a Prospective Study NCT02313259 | CHU de Quebec-Universite Laval | — |
| Completed | Safety and Efficacy Study of rAAV.sFlt-1 in Patients With Exudative Age-Related Macular Degeneration NCT01494805 | Lions Eye Institute, Perth, Western Australia | Phase 1 / Phase 2 |
| Completed | VEGF Trap-Eye: Investigation of Efficacy and Safety in Chinese Subjects With Wet AMD (Age-Related Macular Dege NCT01482910 | Bayer | Phase 3 |
| Terminated | 12 Week Patient Study in Neovascular Age-related Macular Degeneration (AMD) NCT01362348 | GlaxoSmithKline | Phase 2 |
| Withdrawn | Study to Evaluate the Safety and Effectiveness of IRay in Wet Age-related Macular Degeneration (AMD) Patients NCT01339949 | Oraya Therapeutics, Inc. | N/A |
| Completed | Complement Factor H Haplotypes and Smoking in Age-related Macular Degeneration NCT01115231 | VA Office of Research and Development | — |
| Completed | A Single-Center Pilot Study to Assess Macular Function NCT01204541 | ORA, Inc. | — |
| Completed | A Study to Evaluate Pazopanib Tablets in Patients Who Have Neovascular Age-related Macular Degeneration NCT01154062 | GlaxoSmithKline | Phase 1 |
| Completed | Safety And Tolerability Study Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration Includin NCT01003691 | Pfizer | Phase 1 |
| Terminated | HiPED - High Dose Lucentis for Persistent Pigment Epithelial Detachments in Age-related Macular Degeneration NCT01189019 | Anne Fung MD | Phase 2 |
| Completed | Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration NCT01134055 | GlaxoSmithKline | Phase 2 |
| Terminated | Safety and Preliminary Efficacy Study of WST11 (Stakel®)-Mediated VTP Therapy in Subjects With CNV Associated NCT01021956 | Steba Biotech S.A. | Phase 2 |
| Completed | Efficacy Study of Ranibizumab on Patients With Age-related Macular Degeneration. NCT01831947 | Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH | Phase 4 |
| Completed | A Safety Study to Evaluate Pazopanib Eye Drops in Healthy Volunteers NCT01072214 | GlaxoSmithKline | Phase 1 |
| Completed | A Safety Study in Healthy Volunteers to Evaluate Safety, How Fast the Drug is Absorbed, and the Side Effects o NCT01051700 | GlaxoSmithKline | Phase 1 |
| Completed | Safety and Tolerability Study of AAV2-sFLT01 in Patients With Neovascular Age-Related Macular Degeneration (AM NCT01024998 | Genzyme, a Sanofi Company | Phase 1 |
| Unknown | Genetics in Non-response to Anti-VEGF Treatment in Exudative AMD NCT01213667 | University of Cologne | Phase 4 |
| Completed | Reading Performance With a Video Magnifier NCT01670643 | Mary Lou Jackson | — |
| Terminated | A Study of Intravitreal Injections of 2.0mg Ranibizumab in Subjects With Chronic Fluid On OCT Post Multiple In NCT01025232 | David M. Brown, M.D. | Phase 1 / Phase 2 |
| Completed | Macular EpiRetinal Brachytherapy Versus Lucentis® Only Treatment (MERLOT) NCT01006538 | King's College Hospital NHS Trust | Phase 4 |
| Completed | INTREPID - IRay Plus Anti-VEGF Treatment For Patients With Wet AMD NCT01016873 | Oraya Therapeutics, Inc. | Phase 2 |
| Unknown | Study of Intravitreal Microplasmin in Relieving Vitreo-Macular Adhesion in Neovascular Age-related Macular Deg NCT00996684 | University of California, Los Angeles | Phase 2 |
| Completed | Lucentis in Advanced Macular Degeneration NCT00896779 | Steven R. Sanislo | Phase 2 |
| Completed | Does Complement Factor H Gene Polymorphism Play a Role in the Regulation of Vascular Tone in the Choroid? NCT00708929 | Medical University of Vienna | N/A |
| Completed | Safety And Tolerability Study Of RN6G In Patients With Dry, Age-Related Macular Degeneration NCT00877032 | Pfizer | Phase 1 |
| Unknown | Pilot Study to Evaluate the Safety and Efficacy of Treatment With ORA102 Combined With Avastin (Bevacizumab) V NCT00745511 | Ora Bio Ltd. | Phase 1 / Phase 2 |
| Unknown | Efficacy of Ranibizumab in Combination With Photodynamic Therapy for Wet Age-Related Macular Degeneration NCT00813891 | McGill University Health Centre/Research Institute of the McGill University Health Centre | Phase 4 |
| Terminated | Macugen Observational Study NCT00735943 | Pfizer | — |
| Completed | Long-Term Use Of Pegaptanib In Patients For Subfoveal Choroidal Neovascularization Secondary To Age-Related Ma NCT00845273 | Pfizer | — |
| Completed | Pilot Study: A Randomized Trial Of Anesthetic Agents For Intravitreal Injection NCT00769392 | Lahey Clinic | N/A |
| Completed | VEGF-antagonism and Endothelial Function in Age-related Macular Degeneration (AMD) NCT00727753 | University of Zurich | — |
| Unknown | Safety & Tolerability of the IRay System in Subjects With Exudative Choroidal Neovascularization (CNV) Seconda NCT01217762 | Oraya Therapeutics, Inc. | Phase 1 |
| Completed | An Extension to Study MD7108240 NCT00733304 | GlaxoSmithKline | Phase 2 |
| Unknown | Intravitreal Infliximab for Diabetic Macular Edema (DME) and Choroidal Neovascularization (CNV) NCT00695682 | Retina Research Foundation | Phase 1 |
| Completed | An Open Study Comparing the Effects of Moxaverine on Ocular Blood Flow in Patients With Age- Related Macular D NCT00709449 | Medical University of Vienna | Phase 2 / Phase 3 |
| Completed | Safety and Efficacy of Brimonidine Intravitreal Implant in Patients With Geographic Atrophy Due to Age-related NCT00658619 | Allergan | Phase 2 |
| Completed | High Speed Indocyanine Green Angiography Findings in Ranibizumab Treatment for Wet Age-related Macular Degener NCT00656903 | National Eye Institute (NEI) | — |
| Completed | Study Of The Repeat Dosing Of Ketoconazole On The Pharmacokinetics Of A Single Dose Of Pazopanib (GW786034) Ey NCT00659555 | GlaxoSmithKline | Phase 1 |
| Completed | Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Ma NCT00637377 | Bayer | Phase 3 |
| Completed | To Evaluate the Pharmacodynamics, Safety, and Pharmacokinetics of Pazopanib Drops in Adult Subjects With Neova NCT00612456 | GlaxoSmithKline | Phase 2 |
| Terminated | The Effect of a Single Intravitreal Anti-VEGF Therapy on Optic Nerve Head Perfusion NCT00709657 | Medical University of Vienna | N/A |
| Completed | Detection of Neutralizing Antibodies in Patients Treated With Bevacizumab or Ranibizumab NCT00605943 | National Eye Institute (NEI) | — |
| Unknown | VEGF Gene Association With Response to Neovascular Age-related Macular Degeneration With Anti-VEGF Agents NCT01655589 | Institute of Vision, Brasil | — |
| Completed | Potential Research Participants for Future Studies of Inherited Eye Diseases NCT00559234 | National Eye Institute (NEI) | — |
| Unknown | Intravitreal Bevacizumab Combined With PDT Versus Bevacizumab to Treat Exudative AMD NCT00684853 | Federal University of São Paulo | Phase 2 |
| Completed | A Phase 1 Safety Study of Single and Repeated Doses of JSM6427 (Intravitreal Injection) to Treat AMD NCT00536016 | Jerini Ophthalmic | Phase 1 |
| Withdrawn | Subretinal Lucentis for Hemorrhagic Age-related Macular Degeneration (AMD) NCT00538538 | Corewell Health East | Phase 1 |
| Completed | Evaluation of Dosing Interval of Higher Doses of Ranibizumab NCT00533520 | Brandon G. Busbee, MD | Phase 4 |
| Completed | Randomized, Single-Masked, Long-Term, Safety and Tolerability Study of VEGF Trap-Eye in AMD NCT00527423 | Regeneron Pharmaceuticals | Phase 2 |
| Completed | Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macul NCT00509795 | Regeneron Pharmaceuticals | Phase 3 |
| Terminated | Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD NCT00499590 | OPKO Health, Inc. | Phase 3 |
| Terminated | Open-Label, Pilot Study of TG100801 in Patients With Choroidal Neovascularization Due to AMD NCT00509548 | TargeGen | Phase 2 |
| Completed | Reduced Fluence Visudyne-Anti-VEGF-Dexamethasone In Combination for AMD Lesions (RADICAL) NCT00492284 | QLT Inc. | Phase 2 |
| Completed | Ranibizumab and Reduced Fluence PDT for AMD NCT00527475 | Texas Retina Associates | Phase 2 |
| Terminated | Verteporfin Photodynamic Therapy Administered in Conjunction With Ranibizumab in Patients With Subfoveal Choro NCT00433017 | Novartis | Phase 2 / Phase 3 |
| Completed | A Study of Genetic and Environmental Factors and Their Effect on Response to Treatment With Lucentis (Ranibizu NCT00469352 | Oregon Health and Science University | Phase 3 |
| Completed | The Effect of Intravitreal Avastin on the Retina Measured by Electroretinogram NCT00478530 | Sheba Medical Center | N/A |
| Completed | The Optical Coherence Tomography in Age-Related Macular Degeneration Study: The OCT in AMD Study NCT00531141 | The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery | — |
| Unknown | A Study of Strontium90 Beta Radiation With Lucentis to Treat Age-Related Macular Degeneration NCT00454389 | NeoVista | Phase 3 |
| Completed | Scotoma Reduction in AMD Patients Treated With Ranibizumab NCT00467935 | Retina Research Foundation | Phase 1 / Phase 2 |
| Terminated | Influence of Blue Light Filtering Intraocular Lenses on Daytime Levels of Melatonin NCT00444249 | The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery | N/A |
| Completed | A Study To Evaluate The Safety, Tolerability And Pk Of Pazopanib Eye Drops In Healthy Adult And Elderly Subjec NCT00463320 | GlaxoSmithKline | Phase 1 |
| Terminated | Safety and Efficacy of ATG003 in Patients With Wet Age-Related Macular Degeneration (AMD) NCT00414206 | CoMentis | Phase 2 |
| Withdrawn | Combination Therapy for Neovascular Age Related Macular Degeneration NCT00447031 | Yonsei University | N/A |
| Completed | Efficacy/Safety of Verteporfin Photodynamic Therapy and Ranibizumab Compared With Ranibizumab in Patients With NCT00436553 | Novartis | Phase 3 |
| Completed | Anecortave Acetate in Subfoveal Choroidal Neovascularization (CNV) Due to Wet Age-Related Macular Degeneration NCT00051129 | Alcon Research | Phase 3 |
| Completed | Photodynamic and Pharmacologic Treatment of CNV NCT00570193 | Mid-Atlantic Retina Consultations, Inc. | Phase 1 / Phase 2 |
| Completed | A Phase 1 Safety Study of TG100801 Eye Drops in Healthy Volunteers NCT00414999 | TargeGen | Phase 1 |
| Completed | Oxidative Stress in Patients With Age-Related Macular Degeneration NCT00465400 | University Hospital, Basel, Switzerland | — |
| Completed | Metabolic Mapping to Measure Retinal Metabolism NCT00385333 | National Eye Institute (NEI) | Phase 2 |
| Terminated | Bevacizumab in Combination With Verteporfin Reduced and Standard Fluence in the Treatment of Hemorrhaged Lesio NCT00403442 | Vitreous -Retina- Macula Consultants of New York | Phase 1 |
| Completed | Observational Study Of The Long-Term Effect Of Macugen In Patients With Wet Age-Related Macular Degeneration NCT01245387 | Pfizer | — |
| Unknown | Copaxone in Age Related Macular Degeneration NCT00466076 | Kaplan Medical Center | Phase 2 / Phase 3 |
| Completed | Ocular Safety Of Patients Receiving Macugen For Neovascular Age Related Macular Degeneration NCT00460408 | Pfizer | — |
| Completed | MAAM Study: Avastin and Macugen Versus Avastin Versus Macugen NCT00531336 | The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery | Phase 2 |
| Completed | Evaluation Of Safety And Efficacy Of 0.3 Mg/Eye Macugen In Patients With Small Age-Related Macular Degeneratio NCT00324116 | Pfizer | Phase 4 |
| Completed | Phase II Pilot Study of Visudyne® Photodynamic Therapy (PDT) (Low and Very Low Fluence) Combined With Bevacizu NCT00359164 | University of British Columbia | Phase 2 |
| Terminated | Alprostadil in Maculopathy Study (AIMS) NCT00619229 | UCB Pharma | Phase 3 |
| Terminated | An Open Label Trial to Investigate Macugen for the Preservation of Visual Function in Subjects With Neovascula NCT00327470 | Pfizer | Phase 4 |
| Completed | Antioxidant Systems and Age-Related Macular Degeneration NCT00668213 | Vanderbilt University | — |
| Completed | A Long-Term Monitoring Study of the IMT-002 Patients NCT00976235 | VisionCare, Inc. | N/A |
| Terminated | A Study of MSI-1256F (Squalamine Lactate) To Treat "Wet" Age-Related Macular Degeneration NCT00333476 | Genaera Corporation | Phase 2 |
| Terminated | A Clinical Trial to Explore the Safety and Efficacy of Three Different Doses of Pegaptanib Sodium in Patients NCT00312351 | Eyetech Pharmaceuticals | Phase 4 |
| Completed | Combination Bevacizumab and Verteporfin (Two Different Sequences of Treatment)in Neovascular AMD NCT00426998 | Retinal Consultants Medical Group | Phase 2 |
| Completed | Safety and Efficacy of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor (VEGF) Trap NCT00320788 | Regeneron Pharmaceuticals | Phase 2 |
| Unknown | Clinical and Genetic Analyzes of Age-related Macular Degeneration NCT03614481 | Centre Hospitalier Intercommunal Creteil | — |
| Unknown | Long-Term Efficacy in AMD of Rheopheresis in North America NCT00380172 | OccuLogix | N/A |
| Completed | Treatment of Age-Related Macular Degeneration With Anecortave Acetate NCT00211458 | Manhattan Eye, Ear & Throat Hospital | Phase 2 |
| Unknown | Double-Masked Study of Photrex (Rostaporfin) Photodynamic Therapy in the Treatment of Age-Related Macular Dege NCT00157976 | Miravant Pharmaceuticals | Phase 3 |
| Completed | Clinical Study Of Pegaptanib Sodium (EYE001) For Wet-Type Age-Related Macular Degeneration NCT00239928 | Pfizer | Phase 2 |
| Completed | A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Differ NCT00242580 | Novartis Pharmaceuticals | Phase 3 |
| Completed | Systemic Avastin Therapy in Age-Related Macular Degeneration NCT00531024 | The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery | Phase 2 / Phase 3 |
| Completed | Comparison of Reduced Fluence Versus Standard Photodynamic Therapy (in Combination With Intravitreal Triamcino NCT00523406 | Medical University of Vienna | Phase 3 |
| Completed | Study To Determine Safety/Efficacy of Lucentis For Treatment Of Retinal Angiomatous Proliferation Secondary To NCT00395707 | The National Retina Institute | Phase 1 / Phase 2 |
| Completed | Lutein/Zeaxanthin and Omega-3 Supplementation in Persons Over Age 60 NCT00121589 | National Eye Institute (NEI) | Phase 1 |
| Completed | Safety and Efficacy Study of Small Interfering Ribonucleic Acid (RNA) Molecule (Cand5) to Treat Wet Age-Relate NCT00259753 | OPKO Health, Inc. | Phase 2 |
| Completed | Safety and Tolerability Study of Intravitreal VEGF-Trap Administration in Patients With Neovascular AMD NCT00320775 | Regeneron Pharmaceuticals | Phase 1 |
| Completed | Anecortave Acetate in Patients With Exudative Age-related Macular Degeneration (AMD) NCT00299507 | Alcon Research | Phase 3 |
| Completed | Intravitreal v. Sub-tenon Injections of Triamcinolone Acetonide for Macular Edema in Retinal Disorders NCT00101764 | National Eye Institute (NEI) | Phase 1 |
| Completed | Triamcinolone Acetonide Plus Laser Therapy to Treat Age-Related Macular Degeneration NCT00100009 | National Eye Institute (NEI) | Phase 3 |
| Terminated | Study of Talaporfin Sodium Photodynamic Therapy to Treat Advanced Age Related Macular Disease NCT00102115 | Light Sciences LLC | Phase 1 |
| Completed | Tracking Optical Coherence Tomography NCT00343603 | University of Pittsburgh | — |
| Terminated | MSI-1256F (Squalamine Lactate) in Combination With Verteporfin in Patients With "Wet" Age-Related Macular Dege NCT00094120 | Genaera Corporation | Phase 2 |
| Unknown | Safety Study for Treatment of Wet Macular Degeneration Using the TheraSight(TM) Ocular Brachytherapy System NCT00100087 | Theragenics Corporation | Phase 1 / Phase 2 |
| Completed | Open Label Study for the Evaluation of Tolerability of Five Dose Levels of Cand5 NCT00722384 | OPKO Health, Inc. | Phase 1 |
| Completed | A Study of rhuFab V2 (Ranibizumab) in Subjects With Subfoveal Choroidal Neovascularization Secondary to Age-Re NCT00090623 | Genentech, Inc. | Phase 3 |
| Terminated | A Safety and Efficacy Study of MSI-1256F (Squalamine Lactate) To Treat "Wet" Age-Related Macular Degeneration NCT00089830 | Genaera Corporation | Phase 2 |
| Completed | Intravitreous Pegaptanib Sodium Injection in Patients With Exudative Age-Related Macular Degeneration (AMD) NCT00088192 | Eyetech Pharmaceuticals | N/A |
| Completed | Clinical Study Of EYE001 For Wet-Type AMD (Age-Related Macular Degeneration) NCT00150202 | Pfizer | Phase 3 |
| Completed | S0000B: Vitamin E and/or Selenium in Preventing Cataract and Age-Related Macular Degeneration in Men on SELECT NCT00784225 | SWOG Cancer Research Network | Phase 3 |
| Completed | Pegaptanib Sodium on Foveal Thickening in Patients With Exudative Subfoveal Age-Related Macular Degeneration ( NCT00087763 | Eyetech Pharmaceuticals | Phase 2 |
| Completed | Use of Immune Globulin Intravenous (Human) To Treat Age-Related Macular Degeneration NCT00220805 | Grifols Therapeutics LLC | Phase 2 |
| Completed | Eye Injections of Triamcinolone Acetonide for Retinal Blood Vessel Disorders NCT00071227 | National Eye Institute (NEI) | Phase 1 |
| Terminated | Open-Label Posterior Juxtascleral Injections of Anecortave Acetate 15mg Dose for Long Term Use in Patients Wit NCT00065728 | Alcon Research | Phase 3 |
| Completed | Effect of DHA Supplements on Macular Function in Patients With Stargardt Macular Dystrophy and Stargardt-like NCT00060749 | National Eye Institute (NEI) | Phase 1 |
| Completed | A Study to Compare rhuFab V2 With Verteporfin Photodynamic in Treating Subfoveal Neovascular Macular Degenerat NCT00061594 | Genentech, Inc. | Phase 3 |
| Terminated | Genetic Factors in Age-Related Macular Degeneration NCT00058695 | National Eye Institute (NEI) | — |
| Completed | A Study to Evaluate rhuFab V2 in Subjects With Minimally Classic or Occult Subfoveal Neovascular Macular Degen NCT00056836 | Genentech, Inc. | Phase 3 |
| Completed | An Evaluation of Safety and Efficacy of Anecortave Acetate Versus Placebo in Patients With Subfoveal CNV Due t NCT00058994 | Alcon Research | Phase 3 |
| No Longer Available | Treatment of Patients With Age-Related Macular Degeneration With Anecortave Acetate NCT00349739 | University of Iowa | — |
| Completed | Laser and Medical Treatment of Diabetic Macular Edema NCT00050479 | National Eye Institute (NEI) | Phase 3 |
| Completed | Extension Study of rhuFab V2 in Subjects With Neovascular Age-Related Macular Degeneration (AMD) NCT00095433 | Genentech, Inc. | Phase 3 |
| Completed | Efficacy of Electrical Micro-current Retinal Stimulation for Treatment of Dry Age-related Macular Degeneration NCT01600300 | Acuity Medical International, Inc. | Phase 1 / Phase 2 |
| Completed | Celecoxib to Treat Macular Degeneration in Patients Receiving Photodynamic Therapy NCT00043680 | National Eye Institute (NEI) | Phase 2 |
| Completed | Phase 3 Study to Evaluate Anecortave Acetate vs. Visudyne for the Treatment of the Wet Form of AMD NCT00041483 | Alcon Research | Phase 3 |
| Completed | Multi-Ethnic Study of Atherosclerosis (MESA) - Ancillary Eye Study NCT00041444 | University of Wisconsin, Madison | — |
| Completed | Visudyne® in Occult (VIO) NCT00121407 | QLT Inc. | Phase 3 |
| Unknown | A Study to Evaluate Retisert in the Treatment of Patients With the "Wet" Form of Age-Related Macular Degenerat NCT00032396 | Control Delivery Systems | Phase 2 |
| Completed | Phase II/III Study of Anti-VEGF in Neovascular AMD NCT00021736 | Eyetech Pharmaceuticals | Phase 2 / Phase 3 |
| Completed | Identification and Treatment of Feeder Vessels in Macular Degeneration NCT00018070 | National Eye Institute (NEI) | Phase 1 |
| Completed | Preventing Depression in Patients With Macular Degeneration NCT00042211 | Thomas Jefferson University | Phase 3 |
| Completed | Fluocinolone Implant to Treat Macular Degeneration NCT00008515 | National Eye Institute (NEI) | Phase 1 |
| Completed | Lutein for Age-Related Macular Degeneration NCT00006202 | National Eye Institute (NEI) | Phase 2 |
| Unknown | Rheopheresis Blood Filtration Study for the Treatment of Dry Age-Related Macular Degeneration (AMD) NCT00078221 | OccuLogix | Phase 3 |
| Completed | Complications of Age-Related Macular Degeneration Prevention Trial NCT00000167 | National Eye Institute (NEI) | Phase 3 |
| Completed | Submacular Surgery Trials (SST) NCT00000150 | National Eye Institute (NEI) | Phase 3 |
| Completed | Screening for Studies on Retinovascular Diseases NCT00001733 | National Eye Institute (NEI) | — |
| Completed | Phase I Study of Corticosteroid Treatment of Ill-Defined Choroidal Neovascularization in Age-Related Macular D NCT00001615 | National Eye Institute (NEI) | Phase 1 |
| Completed | Long Term Follow-Up of Diabetic Retinopathy NCT00001395 | National Eye Institute (NEI) | — |
| Unknown | Randomized Trials of Vitamin Supplements and Eye Disease NCT00000161 | National Eye Institute (NEI) | Phase 3 |
| Completed | Diabetic Retinopathy and Visual Function Study NCT00001346 | National Eye Institute (NEI) | — |
| Completed | Age-Related Eye Disease Study (AREDS) NCT00000145 | National Eye Institute (NEI) | Phase 3 |
| Unknown | Randomized Trial of Beta-Carotene and Macular Degeneration NCT00000152 | National Eye Institute (NEI) | Phase 3 |
| Unknown | Macular Photocoagulation Study (MPS) NCT00000158 | National Eye Institute (NEI) | Phase 3 |
| Completed | Branch Vein Occlusion Study NCT00000162 | National Eye Institute (NEI) | Phase 3 |
| Completed | Study of AdGVPEDF.11D in Neovascular Age-related Macular Degeneration (AMD) NCT00109499 | GenVec | Phase 1 |
| Completed | Effectiveness of Oral Acetazolamide, Brimonidine Tartarate, and Anterior Chamber Paracentesis in Intraocular P NCT00804921 | University of Sao Paulo | Phase 2 |
| Completed | A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Branch Retinal Vein Occ NCT00308477 | Sanwa Kagaku Kenkyusho Co., Ltd. | Phase 1 / Phase 2 |